Clinical Trial Update: A Phase 1 Study of Alisertib Participants With Advanced Solid Tumors Including Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel Regimen [Phase 1]

View source ↗

Summary

This Phase 1 trial evaluated alisertib in combination with standard docetaxel in patients with advanced solid tumors, including castration-resistant prostate ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Alisertib (alisertib)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Advanced Solid Tumors, Adenocarcinoma of the Prostate | Phase 1 | Status: COMPLETED | Results posted: 2019-02-15